
    
      There will be two groups of treatment in this study who will receive DLBS3233 or placebo of
      DLBS3233 for 12 weeks of therapy.

      Subjects will be provided with an education on lifestyle modification given by the assigned
      nutritionist. All subjects will be advised to follow such a lifestyle modification throughout
      the study period.

      All subjects will be under direct supervision of a medical doctor during the study period.

      All clinical and laboratory examinations to evaluate the investigational drug's efficacy,
      will be performed at baseline, Week 8th and Week 12th (end) of study treatment. Blood glucose
      level (both FPG and 2h-PG) will be performed at baseline and at interval of 4 weeks over the
      12 weeks of study treatment. Safety examinations will be performed at baseline and at the end
      of study. Occurrence of adverse event will be observed during the study.
    
  